250 word limit) Current count=250 words 17 Gepotidacin (formerly GSK2140944) is a novel triazaacenaphthylene bacterial 18 topoisomerase inhibitor with in vitro activity against conventional and biothreat 19 pathogens, including Staphylococcus aureus and Streptococcus pneumoniae. Using 20 neutropenic murine thigh-and lung-infection models, the pharmacokinetics-21 pharmacodynamics (PK-PD) of gepotidacin against S. aureus and S. pneumoniae were 22
9 determination of gepotidacin ELF concentrations for all dosing cohorts at 0.5, 1, 2, 4, 6, 147 8, 12, and 24 h post-dose. The recovered BAL fluid was centrifuged to separate the 148 alveolar macrophages (cell pellet) and the ELF fluid (supernatant) . 149 In order to evaluate the impact of infection on the PK profile of gepotidacin, a second 150 plasma PK study was conducted in both neutropenic infected and uninfected mice 151 administered gepotidacin as a single SC dose of 32 mg/kg and neutropenic infected 152 mice administered gepotidacin 16, 64, and 128 mg/kg. 153 Plasma and BAL samples for the first PK study were assayed for gepotidacin 154 concentrations on two separate occasions by GlaxoSmithKline using a validated high- 155 performance liquid chromatography tandem mass spectrometry method with a lower 156 limit of quantification of 0.05 mg/L and 0.1 mg/L for the plasma samples and 0.0025
Efficacy as Assessed by Change in Bacterial Density

171
Two hours after infection for the murine-thigh infection model studies and 4 h after 172 infection for the murine-lung infection model studies, gepotidacin treatment regimens 173 were administered as 0.2 mL SC injections and continued for a 24 h period in all 174 studies. Control animals received sterile, normal saline using the same volume, route, 175 and schedule as the active-treatment regimens. Non-drug treated control animals were 176 sacrificed just prior to antibiotic initiation (0 h) and after 24 h. All animals were 177 euthanized by carbon dioxide asphyxiation followed by cervical dislocation. After 178 sacrifice, mice in the murine-thigh infection models had their thighs removed and 179 individually homogenized in normal saline. Serial dilutions of the thigh homogenates 180 were plated for CFU determination and incubated overnight at 37°C. Counts from each 181 thigh were considered as independent observations. Similarly, for the murine-lung 182 infection model, following euthanasia, the lungs were aseptically excised, homogenized, 183 diluted, plated, and incubated. Viable plate counts were determined as log 10 CFU per 184 thigh or lung. Efficacy was calculated as the change in the log 10 CFU obtained for 185 antibiotic-treated mice after 24 h compared with the pre-antibiotic baseline CFU 186 measured for the 0 h control animals.
188
Dose-Fractionation Studies
189
Dose-fractionation studies were conducted in neutropenic mice infected in each thigh 190 with S. aureus 33591 or S. pneumoniae 10813. Groups of two mice each were 191 administered gepotidacin total daily doses of 2, 8, 32, 128, or 512 mg/kg SC divided evenly every 3, 6, 12, or 24 h. Untreated mice for the growth control assessment were 193 euthanized at 2 and 24 h after inoculation. 
Pharmacokinetic Model Development
The murine plasma and ELF concentration data from uninfected mice from the first PK 215 study were fit by candidate PK models using maximum likelihood objective function, as 216 is implemented in S- ADAPT 1.57 [18] . Weighting of the plasma and ELF concentrations 217 was based on the reciprocal of the estimated observation variance (the error model 218 standard deviation (SD) squared), which was predicted as a function of the fitted 219 concentrations. Given that the study design for PK sampling was destructive in nature 220 (i.e., animals were sacrificed at the evaluated time points), the data were combined and 221 fit using a pooled PK analysis approach.
223
Calculation of ELF Penetration Ratio
224 Using the PK model described above that was developed using data from uninfected 225 mice from the first PK study, fitted total-drug plasma and ELF concentration-time The gepotidacin MIC ranges for the isolates evaluated were 0.5 to 2 mg/L for S. aureus 309 and 0.125 to 1 mg/L for S. pneumoniae. The gepotidacin MIC values for all isolates are 310 shown in Table 1 . The plasma and ELF PK of gepotidacin based on the first study in uninfected mice were 314 best described by a four-compartment model with three compartments for plasma, one 315 compartment for ELF, linear distributional clearances, a parallel first-order and capacity-316 limited clearance, and a first-order absorption rate. The PK data were well fit by the PK Table 2 shows the PK model 322 parameter estimates and standard errors. As evidenced by the rate constants for the 323 distribution of gepotidacin into (k ce ) and the removal from the ELF (k ec ), gepotidacin 324 rapidly penetrates and departs the ELF compartment of mice and does not accumulate.
325
The ELF penetration ratio for gepotidacin in non-infected neutropenic mice was 0.65 326 across all of the doses assessed. Since the k ce and k ec rate constants were determined 327 without variability across doses, the above-described ELF penetration ratio estimate 328 was independent of dose. In summary, using PK data from neutropenic mice and data from a murine-thigh 504 infection model in which mice were infected with S. aureus or S. pneumoniae, free-drug 505 plasma AUC:MIC ratio was identified as the PK-PD index most associated with the 506 efficacy of gepotidacin. Data from these studies also allowed for characterization of the b. E con =the change from baseline in log 10 CFU at 24 h; E max =the maximum change in log 10 CFU from E con ; EC 50 =the free-drug plasma AUC:MIC ratio associated with half-maximal effect; Hill=the Hill coefficient; and Sd int =the intercept term for the error variance model. c. EC 50 was modeled as normally distributed and as such, the arithmetic mean and standard deviation is reported.
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